We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

48 hedge funds and large institutions have $106M invested in Inhibikase Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

4.1% more ownership

Funds ownership: 69.23% → 73.33% (+4.1%)

2% more funds holding

Funds holding: 47 → 48 (+1)

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $113M → $106M (-$6.4M)

Holders
48
Holders Change
+1
Holders Change %
+2.13%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
24
Increased
11
Reduced
6
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.51M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.45M
3
Blackstone Inc
Blackstone Inc
New York
+$1.11M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$736K
5
State Street
State Street
Massachusetts
+$697K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2M
2
PA
Perceptive Advisors
New York
-$965K
3
Goldman Sachs
Goldman Sachs
New York
-$364K
4
SCM
Stonepine Capital Management
Oregon
-$355K
5
Marshall Wace
Marshall Wace
United Kingdom
-$340K
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
51
Marshall Wace
United Kingdom
– -$340K -155,270 Closed
Jane Street
52
Jane Street
New York
– -$255K -116,249 Closed
Balyasny Asset Management
53
Balyasny Asset Management
Illinois
– -$178K -81,161 Closed
HF
54
HRT Financial
New York
– -$144K -65,906 Closed
OAC
55
OMERS Administration Corp
Ontario, Canada
– -$123K -56,000 Closed
JG
56
Jain Global
New York
– -$120K -54,845 Closed
Qube Research & Technologies (QRT)
57
Qube Research & Technologies (QRT)
United Kingdom
– -$78K -35,625 Closed
ECM
58
ExodusPoint Capital Management
New York
– -$71K -32,538 Closed
DC
59
Diametric Capital
Massachusetts
– -$62.1K -28,366 Closed
YIH
60
Y-Intercept (HK)
Hong Kong
– -$58.6K -26,775 Closed
SSA
61
Schonfeld Strategic Advisors
New York
– -$37K -16,876 Closed
PAS
62
Point72 Asia (Singapore)
Singapore
– -$32.8K -14,976 Closed
JFG
63
Jefferies Financial Group
New York
– -$32.4K -14,800 Closed
CFM
64
Catalyst Funds Management
Australia
– -$30K -13,712 Closed
Stifel Financial
65
Stifel Financial
Missouri
– -$28.8K -13,129 Closed
QC
66
Quantessence Capital
New York
– -$28.5K -13,005 Closed
PCM
67
Prelude Capital Management
New York
– -$24.3K -11,098 Closed
Capstone Investment Advisors
68
Capstone Investment Advisors
New York
– -$24.2K -11,067 Closed
BHCM
69
Brevan Howard Capital Management
Jersey
– -$22.7K -10,384 Closed
CSS
70
Cubist Systematic Strategies
Connecticut
– -$19.8K -9,043 Closed
PD
71
Point72 (DIFC)
United Arab Emirates
– -$4.34K -1,980 Closed
1 2
3

IKT Hedge Fund Activity: Q2 2025 in Review

48 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2025, worth a combined $106M — down 5.7% from $113M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new IKT positions and 23 closed out — a net gain of 1 holder — while 11 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $4.51M. The largest seller was Millennium Management, exiting entirely with an estimated $2M sold.

  • 48 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2025, up from 47 in Q1 2025.
  • Funds reported $106M of Inhibikase Therapeutics stock for Q2 2025, down 5.7% quarter-over-quarter.
  • 24 funds opened new Inhibikase Therapeutics positions in Q2 2025 and 23 closed out, a net change of +1 holder.
  • The largest Inhibikase Therapeutics buyer in Q2 2025 was BlackRock, an estimated $4.51M added.
  • The largest Inhibikase Therapeutics seller in Q2 2025 was Millennium Management, an estimated $2M sold.

Based on aggregated 13F filings for Q2 2025.